Enliven Therapeutics Inc
(ELVN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 292,102 | 75,536 | 49,491 | 30,433 | 36,484 |
| Marketable Securities | N/A | N/A | 6,813 | 29,907 | 36,416 |
| TOTAL | $298,003 | $77,753 | $59,104 | $64,256 | $78,528 |
| Non-Current Assets | |||||
| PPE Net | 853 | 890 | 0 | 105 | 588 |
| Other Non-Current Assets | 4,010 | 4,655 | 0 | 305 | 2,486 |
| TOTAL | $4,863 | $5,545 | $N/A | $410 | $3,074 |
| Total Assets | $302,866 | $83,298 | $59,104 | $64,666 | $81,602 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,860 | 3,438 | 767 | 1,135 | 1,884 |
| Accrued Expenses | 5,082 | 6,277 | 1,051 | 1,722 | 4,831 |
| TOTAL | $10,942 | $9,715 | $1,818 | $3,302 | $7,223 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 508 | 659 | 0 | 0 | 1,967 |
| TOTAL | $508 | $659 | $N/A | $N/A | $1,967 |
| Total Liabilities | $11,450 | $10,374 | $1,818 | $3,302 | $9,190 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 41,115 | 6,558 | 6,572 | 6,572 | 6,569 |
| Common Shares | 41 | 1 | 27 | 27 | 27 |
| Retained earnings | -97,588 | -82,864 | -178,194 | -173,585 | -162,136 |
| Other shareholders' equity | 0 | 149,749 | -4 | -35 | -51 |
| TOTAL | $291,416 | $72,924 | $57,286 | $61,364 | $72,412 |
| Total Liabilities And Equity | $302,866 | $83,298 | $59,104 | $64,666 | $81,602 |